3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
240
Gastrointestinal
95
Head & Neck
35
CNS
27
Tumor-Agnostic
22
Sarcoma
22
Genitourinary
22
Other solid neoplasm
17
Breast
16
Gynecologic
12
Other hematologic neoplasm
3
Lymphoid
3
Dermatologic
3
Myeloid
2
Plasma cell
1
Other neoplasm
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Dexamethasone
393
Bortezomib
246
Lenalidomide
222
Cyclophosphamide
184
Melphalan
168
Calcium Dobesilate
119
Peripheral Blood Stem Cell Transplantation
94
fludarabine phosphate
89
Thalidomide
82
Filgrastim
74
carfilzomib
70
pomalidomide
68
Granulocyte Colony-Stimulating Factor
63
Busulfan
63
Mycophenolic Acid
61
daratumumab
58
Whole-Body Irradiation
57
ixazomib
54
fludarabine
52
Tacrolimus
52
Prednisone
51
Cyclosporine
50
Antilymphocyte Serum
35
dexamethasone acetate
32
plerixafor
30
Etoposide
30
Methotrexate
29
Radiotherapy
28
dexamethasone 21-phosphate
27
Doxorubicin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Erlotinib Hydrochloride
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled